M.D. Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma.

Ranjit Nair,Chelsea C. Pinnix,Jillian R. Gunther,Paolo Strati,Jason R. Westin,Luis Fayad,Fredrick B. Hagemeister,Swaminathan Padmanabhan Iyer,Loretta J. Nastoupil,Simrit Parmar,Maria A. Rodriguez,Raphael Steiner,Bouthaina S. Dabaja,Penny Fang,Christopher R. Flowers,Mansoor Noorani,Lei Feng,Sattva S. Neelapu,Sairah Ahmed,Hun Ju Lee

M.D. Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma.

2020

e20013Background: Nivolumab and Pembrolizumab are effective immune checkpoint inhibitor (ICI) therapies targeting PD-1/ PDL-1 immune axis. The drugs are currently approved for relapsed/ refractory ...

Keywords:

immune checkpoint inhibitors
Pathology
Cancer research
Medicine
Classical Hodgkin lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations